Zongertinib (BI1810631), an irreversible HER2 TKI spares EGFR signaling and improves therapeutic response in preclinical models and patients with HER2-driven cancers

被引：0
|
作者：
Neumueller, R. [1 ]
Wilding, B. [1 ]
Augsten, M. [1 ]
Baum, A. [1 ]
Chylinski, K. [1 ]
Waizenegger, I. [1 ]
Woelflingseder, L. [1 ]
Solca, F. [1 ]
Kraut, N. [1 ]
机构：
[1] Boehringer Ingelheim RCV, Oncol Res, Vienna, Austria
来源：
EUROPEAN JOURNAL OF CANCER | 2024年 / 211卷
关键词：
D O I：
10.1016/j.ejca.2024.114659
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PB124
引用
收藏
页码：S56 / S56
页数：1
相关论文
共 29 条
  • [11] ACTIVITY OF BIBW 2992, AN IRREVERSIBLE EGFR/HER1 AND HER2 TKI, IN LUNG ADENOCARCINOMA PATIENTS HARBORING LESS COMMON EGFR MUTATIONS
    Shih, J.
    Yu, C.
    Su, W.
    Hsia, T.
    Graziano, S. L.
    Calvo, R.
    Cong, X. J.
    Shahidi, M.
    Yang, C.
    Miller, V.
    ANNALS OF ONCOLOGY, 2010, 21 : 138 - 138
  • [12] Beamion Lung 1, an ongoing phase Ia/Ib trial of the HER2 TKI, BI 1810631 in patients (pts) with advanced solid tumors with HER2 aberrations: Latest data
    Opdam, F.
    Heymach, J.
    Ruiter, G.
    Barve, M.
    Tu, H.
    Wu, Y-L.
    Schroeter, L.
    Sadrolhefazi, B.
    Serra, J.
    Yoh, K.
    Yamamoto, N.
    ANNALS OF ONCOLOGY, 2023, 34
  • [13] Beamion LUNG-1, a phase Ia/Ib trial of the HER2-specific tyrosine kinase inhibitor, zongertinib (BI 1810631), in patients with HER2driven tumours: outcomes according to HER2 aberration type in lung and other tumours
    Feuersinger, A.
    Opdam, F.
    Heymach, J.
    Barve, M.
    Tu, H.
    Wu, Y.
    Berz, D.
    Mueller, A. M.
    von Wangenheim, U.
    Serra, J.
    Yoh, K.
    Yamamoto, N.
    VIRCHOWS ARCHIV, 2024, 485 : S425 - S426
  • [14] BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
    Li, D.
    Ambrogio, L.
    Shimamura, T.
    Kubo, S.
    Takahashi, M.
    Chirieac, L. R.
    Padera, R. F.
    Shapiro, G. I.
    Baum, A.
    Himmelsbach, F.
    Rettig, W. J.
    Meyerson, M.
    Solca, F.
    Greulich, H.
    Wong, K-K
    ONCOGENE, 2008, 27 (34) : 4702 - 4711
  • [15] BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
    D Li
    L Ambrogio
    T Shimamura
    S Kubo
    M Takahashi
    L R Chirieac
    R F Padera
    G I Shapiro
    A Baum
    F Himmelsbach
    W J Rettig
    M Meyerson
    F Solca
    H Greulich
    K-K Wong
    Oncogene, 2008, 27 : 4702 - 4711
  • [16] New method to measure functional HER2-driven signaling activity in primary tumor cells identifies HER2-negative breast cancers with abnormal HER2 signaling activity: New group of patients may benefit from anti-HER2 therapy
    Laing, L.
    Burns, D.
    MacNeil, I.
    Rich, B.
    Huang, Y.
    Myhre, S.
    Soltani, S.
    Sullivan, B.
    CANCER RESEARCH, 2017, 77
  • [17] Phase I Beamion Lung 1 trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations: Updated data.
    Heymach, John
    Opdam, Frans
    Barve, Minal A.
    Tu, Hai-Yan
    Wu, Yi-Long
    Berz, David
    Gibson, Neil
    Sadrolhefazi, Behbood
    Serra, Josep
    Yoh, Kiyotaka
    Yamamoto, Noboru
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [18] Updated data from the Phase I Beamion Lung 1 trial of the HER2 tyrosine kinase inhibitor (TKI), BI 1810631, as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations
    Heymach, John
    Opdam, Frans
    Barve, Minal
    Tu, Hai-Yan
    Wu, Yi-Long
    Gibson, Neil
    Sadrolhefazi, Behbood
    Serra, Josep
    Yoh, Kiyotaka
    Yamamoto, Noboru
    CANCER RESEARCH, 2023, 83 (08)
  • [19] Measuring functional HER2-driven signaling status ex vivo to predict response to HER2 therapy: Results from a mouse breast tumor xenograft study.
    Laing, Lance G.
    Burns, David J.
    Huang, Yao
    MacNeil, Ian A.
    Rich, Benjamin E.
    Soltani, Sajjad
    Myhre, Samantha
    Sullivan, Brian
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [20] HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
    Gan, Jiadi
    Huang, Yihua
    Liao, Jun
    Pang, Lanlan
    Fang, Wenfeng
    ONCOTARGETS AND THERAPY, 2021, 14 : 5297 - 5307
123